Status:

COMPLETED

Propofol Injection for Daily Headache

Lead Sponsor:

University of Alberta

Conditions:

Chronic Headache

Analgesic Rebound Headache

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

Hypothesis A single subanesthetic dose of propofol will result in improved pain and quality of life for the next 30 days in persons with chronic daily headache (CDH) Specific objectives To measure th...

Detailed Description

Chronic daily headache (CDH) is a common and extremely disabling pain syndrome with a recent estimated point prevalence of 2.98% of the general population1 Other studies estimate a prevalence of 4.1% ...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • Adult subjects (18-65 years) with CDH by the criteria of Silberstein and Lipton.41 i.e. on the basis of pre-randomization history suffer chronic headaches lasting more than 4 hours a day for more than 15 days a month.
  • Previously investigated to exclude serious treatable pathology.
  • On the basis of the pre-randomization headache diary: the average pain intensity during each episode should be at least 5 /10 on the Numerical Rating Scale (NRS) on 4 days out of 7.
  • Quality of life and function should be impaired as evidenced by a (pre-randomization) Headache Disability Index (HDI) of at least 40.
  • Exclusion criteria
  • History of the following:
  • Known or suspected allergy to propofol, intralipid or midazolam,
  • In emergency or life-threatening situations,
  • Those having language barriers (e.g. illiterate, not English-speaking, dysphasic),
  • Known or suspected difficult airway or sleep apnea,
  • Severe respiratory disease,
  • Neuromuscular disease,
  • Seizure disorder,
  • Severe cardiac disease,
  • Severe gastroesophageal reflux disease,
  • Pancreatitis,
  • Lipid disorders,
  • Receiving Total Parenteral Nutrition,
  • Body mass index \> 35, diabetes or major endocrine disorder,
  • Hepatic or renal failure,
  • Unstable psychiatric disorder,
  • Known drug abuse,
  • Pregnancy,
  • Cognitively impaired.

Exclusion

    Key Trial Info

    Start Date :

    September 1 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    November 1 2007

    Estimated Enrollment :

    28 Patients enrolled

    Trial Details

    Trial ID

    NCT00228267

    Start Date

    September 1 2004

    End Date

    November 1 2007

    Last Update

    May 4 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Multidisciplinary Pain Centre, Univ. Alta Hospital

    Edmonton, Alberta, Canada, T6G 2B7

    Propofol Injection for Daily Headache | DecenTrialz